Close Menu

NEW YORK (GenomeWeb) – Biocept said today that it has reached an agreement for the validation and potential adoption of its Target Selector liquid biopsy kits in Agiomix's lab in the United Arab Emirates lab.

Agiomix will test the kits to ensure comparability of results achieved in Biocept's San Diego CLIA-certified, CAP-accredited facility. Subject to that validation, Agiomix would then purchase the kits for use in its genomics test services, analyzing samples received from the Middle East, Africa, and Asia.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.